Clinical evaluation of VIMANG® in the treatment of oral homogenous leucoplakia
Abstract
Introduction: oral leukoplakia is the most frequent premalignant lesion in the world; in the province of Ciego de Ávila, more than 100 cases are diagnosed annually. Among the natural antioxidant products that can stop the evolutionary process of cancer is the VIMANG®, made from the bark of Mangifera indica L, with proven antioxidant effects in vivo and in vitroalthough its therapeutic use is poorly treated in the medical literature.Objective: to evaluate the use of VIMANG® in the treatment of homogeneous oral leukoplakia.
Method: a monocentric study of therapeutic extension was carried out at the Maxillofacial Surgery Service of the Provincial General Teaching Hospital "Dr. Antonio Luaces Iraola" in Ciego de Ávila from January to December 2014; the sample consisted of 60 patients diagnosed with homogeneous oral leukoplakia, which were distributed in an experimental group (treated with VIMANG®) and a control group (treated with vitamins). The responses to treatment were evaluated in the initial, intermediate and final phases, as well as adverse reactions and patient compliance.
Results: the majority of patients in both groups had risk factors for the disease (smoking, alcoholism, clear skin and residents in urban areas); lesions on the lips were the most frequent. Regardless of these factors, 76,7 % of the patients in the experimental group and 63,3 % of the control group evolved favorably.
Conclusions: VIMANG® was more effective in treating homogeneous oral leukoplakia than conventional therapy.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ramón Antonio Mesa Gómez, Manuel de Jesús Díaz Hernández, Jorge Enrique Aragón Abreu, Sady Machado Ramos, Rafael Castañeda Molerio, Delvis Manuel Díaz Martí
This work is licensed under a Creative Commons Attribution 4.0 International License.
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
